264 related articles for article (PubMed ID: 6722813)
1. Chemoimmunotherapy of B 16 melanoma and P388 leukemia with cyclophosphamide and pyrimidinones.
Li LH; Johnson MA; Moeller RB; Wallace TL
Cancer Res; 1984 Jul; 44(7):2841-7. PubMed ID: 6722813
[TBL] [Abstract][Full Text] [Related]
2. Mechanism of antitumor action of pyrimidinones in the treatment of B16 melanoma and P388 leukemia.
Li LH; Wallace TL; Richard KA; Tracey DE
Cancer Res; 1985 Feb; 45(2):532-8. PubMed ID: 3967227
[TBL] [Abstract][Full Text] [Related]
3. Relationship between modulation of natural killer cell activity and antitumor activity of bropirimine when used in combination with various types of chemotherapeutic drugs.
Li LH; DeKoning TF; Wallace TL
Cancer Res; 1987 Nov; 47(22):5894-900. PubMed ID: 3664490
[TBL] [Abstract][Full Text] [Related]
4. Antitumor activity of pyrimidinones, a class of small-molecule biological response modifiers.
Li LH; Wallace TL; Wierenga W; Skulnick HI; DeKoning TF
J Biol Response Mod; 1987 Feb; 6(1):44-55. PubMed ID: 3559628
[TBL] [Abstract][Full Text] [Related]
5. Effect of mouse hepatitis virus infection on combination therapy of P388 leukemia with cyclophosphamide and pyrimidinones.
Li LH; DeKoning TF; Nicholas JA; Kramer GD; Wilson D; Wallace TL; Collins MJ
Lab Anim Sci; 1987 Feb; 37(1):41-4. PubMed ID: 3035278
[TBL] [Abstract][Full Text] [Related]
6. Schedule-dependent variations in the response of murine P388 leukemia to cyclophosphamide in combination with interferons-alpha/beta.
Borden EC; Sidky YA; Hatcher JF; Bryan GT
Cancer Res; 1988 May; 48(9):2329-34. PubMed ID: 3356000
[TBL] [Abstract][Full Text] [Related]
7. Immunogenicity of the tumor determines the outcome of immunotherapy with interleukin-2, ABPP, and cyclophosphamide of micro- and macrometastatic intraperitoneal tumor.
Eggermont AM; Sugarbaker PH
Cancer Detect Prev; 1990; 14(4):483-90. PubMed ID: 2224911
[TBL] [Abstract][Full Text] [Related]
8. Chemotherapy with [SP-4-3-(R)]-[1,1-cyclobutanedicarboxylato(2-)](2- methyl-1,4-butanediamine-N,N')platinum (CI-973, NK121) in combination with standard agents against murine tumors in vivo.
Elliott WL; Roberts BJ; Howard CT; Leopold WR
Cancer Res; 1994 Aug; 54(16):4412-8. PubMed ID: 8044790
[TBL] [Abstract][Full Text] [Related]
9. Antileukemic effects of recombinant human tumor necrosis factor alpha (rh-TNF alpha) with cyclophosphamide or methotrexate on leukemia L1210 and leukemia P388 in mice.
Warzocha K; Robak T
Acta Haematol Pol; 1992; 23(1):55-62. PubMed ID: 1615753
[TBL] [Abstract][Full Text] [Related]
10. The effect of high-dose thiotepa, alone or in combination with other chemotherapeutic agents, on a murine B-cell leukemia model simulating autologous stem cell transplantation.
Abdul-Hai A; Weiss L; Ergas D; Resnick IB; Slavin S; Shapira MY
Bone Marrow Transplant; 2007 Nov; 40(9):891-6. PubMed ID: 17768389
[TBL] [Abstract][Full Text] [Related]
11. Synergistic action of 2-chlorodeoxyadenosine and cyclophosphamide on murine leukemias L1210 and P388.
Góra-Tybor J; Robak T
Acta Haematol Pol; 1993; 24(2):177-82. PubMed ID: 8103959
[TBL] [Abstract][Full Text] [Related]
12. Antitumor activity and biochemical effects of aphidicolin glycinate (NSC 303812) alone and in combination with cisplatin in vivo.
O'Dwyer PJ; Moyer JD; Suffness M; Harrison SD; Cysyk R; Hamilton TC; Plowman J
Cancer Res; 1994 Feb; 54(3):724-9. PubMed ID: 8306334
[TBL] [Abstract][Full Text] [Related]
13. Treatment of spontaneous leukemia in AKR mice with chemotherapy, immunotherapy, or interferon.
Bekesi JG; Roboz JP; Zimmerman E; Holland JF
Cancer Res; 1976 Feb; 36(2 pt 2):631-9. PubMed ID: 1082796
[TBL] [Abstract][Full Text] [Related]
14. Sequence and schedule-dependent synergy of trimetrexate in combination with 5-fluorouracil in vitro and in mice.
Elliott WL; Howard CT; Dykes DJ; Leopold WR
Cancer Res; 1989 Oct; 49(20):5586-90. PubMed ID: 2477146
[TBL] [Abstract][Full Text] [Related]
15. Combination chemotherapy and IL-15 administration induce permanent tumor regression in a mouse lung tumor model: NK and T cell-mediated effects antagonized by B cells.
Chapoval AI; Fuller JA; Kremlev SG; Kamdar SJ; Evans R
J Immunol; 1998 Dec; 161(12):6977-84. PubMed ID: 9862733
[TBL] [Abstract][Full Text] [Related]
16. Combined effects of immunity and antitumor drugs against cancer. I. In vivo studies with cis-diamminedichloroplatinum and cyclophosphamide in mouse models.
Ricci F; De Filippi R; Riccardi C; Romani L; Giuliani A
Chemioterapia; 1987 Dec; 6(6):403-9. PubMed ID: 3435922
[TBL] [Abstract][Full Text] [Related]
17. Activity of a novel anthracenedione, 1,4-dihydroxy-5,8-bis(((2-[(2-hydroxyethyl)amino]ethyl)amino])-9,10-anthracenedione dihydrochloride, against experimental tumors in mice.
Wallace RE; Murdock KC; Angier RB; Durr FE
Cancer Res; 1979 May; 39(5):1570-4. PubMed ID: 427798
[TBL] [Abstract][Full Text] [Related]
18. Successful immunotherapy of mouse melanoma and sarcoma with recombinant interleukin-2 and cyclophosphamide.
Silagi S; Schaefer AE
J Biol Response Mod; 1986 Oct; 5(5):411-22. PubMed ID: 3490544
[TBL] [Abstract][Full Text] [Related]
19. Comparative antitumor effects of Corynebacterium parvum, Bordetella pertussis, Bacillus Calmette-Guérin, and levamisole alone or in combination with cyclophosphamide in the CaD2 murine mammary adenocarcinoma system.
Purnell DM; Bartlett GL; Kreider JW; Biro TG; Kontra J
Cancer Res; 1979 Dec; 39(12):4838-42. PubMed ID: 498111
[TBL] [Abstract][Full Text] [Related]
20. Antitumour and antimetastatic effect of genistein alone or combined with cyclophosphamide in mice transplanted with various tumours depends on the route of tumour transplantation.
Wietrzyk J; Opolski A; Madej J; Radzikowski C
In Vivo; 2000; 14(2):357-62. PubMed ID: 10836210
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
